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Background
MEDI-551, an IgG1k antibody-dependent cellular cyto-
toxicity (ADCC) enhanced anti-CD19 monoclonal anti-
body (mAb), has a single-agent response rate of 24%
(12% with complete remission [CR]) in heavily pre-
treated patients with diffuse large B cell lymphoma
(DLBCL). MEDI0680 (AMP-514) a humanized IgG4
mAb against PD-1, blocks inhibitory PD-1 receptors
(PD-L1) on T cells to augment immune responses. A
combination of MEDI-551/MEDI0680 (AMP-514) may
link the intrinsic cytotoxic capability of MEDI-551 with
an agent that primes the immune cells required for
ADCC or may augment immune responses from tumor
cell death by MEDI-551. This study explores this novel
combination regimen in patients with multiply relapsed/
refractory (R/R) DLBCL who have limited opportunities
for cure, and may offer a regimen with less toxicity but
equal or better efficacy versus traditional chemotherapy.
Study D2852C00004, a Phase Ib/2 dose escalation/
expansion study, will determine the maximum tolerated
dose (MTD) or the highest protocol-defined dose
(HPDD) safety, and activity of the combination of
MEDI-551/MEDI0680 (AMP-514) in R/R DLBCL
patients who have failed 1-2 prior lines of therapy.
Study objectives
Primary objectives: to determine the MTD or HPDD
(in the absence of exceeding the MTD) of MEDI-551/
MEDI0680 (AMP-514); dose expansion: to evaluate the
safety, tolerability, and clinical activity of MEDI-551/
MEDI0680 (AMP-514). Secondary objective: to evaluate
the pharmacokinetics and antidrug antibodies of MEDI-
551/MEDI0680 (AMP-514) in patients with R/R DLBCL.
Exploratory objectives will determine the impact of tumor
PD-L1 expression on clinical activity of the combination
and will follow soluble PD-1 and PD-L1 expression as bio-
markers of activity.
Study design
Standard 3+3 design to determine the MTD of the com-
bination of MEDI-551/MEDI0680 (AMP-514). Patients
will receive MEDI-551 12 mg/kg once monthly with 1 of
3 possible doses of MEDI0680 administered bimonthly
for 1 year. Thereafter, patients will continue MEDI-551
monthly until progressive disease or toxicity. If a patient
experiences progressive disease beyond 12 months of
therapy while still receiving MEDI-551 treatment, combi-
nation treatment with MEDI0680 (AMP-514) may be
resumed for up to 12 additional months. After MTD
identification, additional patients will be enrolled in the
dose expansion portion to ensure a total sample size of
26 efficacy-evaluable patients. Thirteen of 26 efficacy-
evaluable patients receiving the MTD will be required to
have PD-L1 expression. Patients will be stratified by
refractoriness to chemotherapy, and CD20 therapy and
PD-L1 status. Results will inform additional studies to
find a chemotherapy-free regimen for frail R/R DLBCL
patients.
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